| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 519.40 | 5.1% | 6.0% |
| Total Income | 526.00 | 5.8% | 4.9% |
| Expenditure | 470.60 | 0.5% | 2.9% |
| PBT | 8.30 | 190.2% | 87.8% |
| Net Profit | 14.40 | 344.1% | 71.3% |
| OPM | 11.22% | 2.18pp | 11.12pp |
| NPM | 2.74% | 3.93pp | 6.34pp |
| EPS | 1.17 | 143.8% | 71.3% |
Hikal Ltd FY26: Revenue ₹1,713 Cr, PAT ₹14 Cr
27 May 2026 · 27 May, 5:02 pm
Summary
Hikal Ltd. announced its audited financial results for Q4 and the full financial year ended March 31, 2026. For Q4FY26, the company reported consolidated revenue of ₹519 crore, with an EBITDA of ₹105 crore and a margin of 20.3%. Profit after tax for the quarter was ₹14 crore, indicating a recovery from a loss in the previous quarter. For the entire fiscal year 2026, Hikal posted a consolidated revenue of ₹1,713 crore with an EBITDA margin of 12.9%. Management highlighted a decisive shift from remediation to sustainable growth, citing improvements in operating performance, strengthened quality systems, and strategic investments in future-ready capabilities as key drivers, noting that the worst of the volume cycle in Crop Protection appears to be over.
Key Highlights
- 1
Hikal Limited reported consolidated revenue of ₹519 crore for Q4FY26, which is an increase of approximately 5.1% quarter-on-quarter, despite a year-on-year decrease of about 6%.
- 2
Consolidated EBITDA for Q4FY26 stood at ₹105 crore, with an EBITDA margin of 20.3%, showing a quarter-on-quarter growth of 26.5% but a year-on-year decline of 14.6%.
- 3
Profit after tax (PAT) for Q4FY26 was ₹14 crore, a significant recovery from a loss of ₹6 crore in Q3FY26, although it represents a 72% decrease from ₹50 crore in Q4FY25.
- 4
For the full financial year 2026, the company achieved a consolidated revenue of ₹1,713 crore and an EBITDA margin of 12.9%.
- 5
The Crop Protection business demonstrated robust performance in Q4FY26, with revenues growing by 45% quarter-on-quarter and 13% year-on-year to ₹228 crore.
- 6
Hikal’s board approved a final dividend of 20% of face value, bringing the total dividend for the financial year to 30%.
- 7
Strategic investments in HPAPI and ADC-related chemistries, alongside an expanded Pune kilo lab, are strengthening the company's integrated end-to-end CDMO capabilities.
Informational and educational content only. Not investment advice.